Pharmacological Treatment of Social Anxiety Disorder.

2007 ◽  
pp. 173-199
Author(s):  
Deborah C. Beidel ◽  
Samuel M. Turner
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment

Pediatric Social Anxiety Disorder: Predictors of Response to Pharmacological Treatment

2012 ◽  
Vol 22 (6) ◽  
pp. 410-414 ◽  
Author(s):  
Gabriele Masi ◽  
Chiara Pfanner ◽  
Maria Mucci ◽  
Stefano Berloffa ◽  
Angela Magazù ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Predictors Of Response

scholarly journals Korean Guidelines for the Pharmacological Treatment of Social Anxiety Disorder: Initial Treatment Strategies

2018 ◽  
Vol 15 (2) ◽  
pp. 147-155
Author(s):  
Hyungkun Yoon ◽  
Dong Jae Oh ◽  
Ho-Suk Suh ◽  
Kyoung-Uk Lee ◽  
Se-Won Lim ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Initial Treatment ◽  
Treatment Strategies

scholarly journals The evidence-based pharmacological treatment of social anxiety disorder

2003 ◽  
Vol 6 (4) ◽  
pp. 427-442 ◽  
Author(s):  
Carlos Blanco ◽  
Muhammad S. Raza ◽  
Franklin R. Schneier ◽  
Michael R. Liebowitz
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Evidence Based

scholarly journals The evidence-based pharmacotherapy of social anxiety disorder

2013 ◽  
Vol 16 (1) ◽  
pp. 235-249 ◽  
Author(s):  
Carlos Blanco ◽  
Laura B. Bragdon ◽  
Franklin R. Schneier ◽  
Michael R. Liebowitz
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Monoamine Oxidase ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Monoamine Oxidase A ◽  
Treatment Resistant ◽  
First Line ◽  
First Line Therapy

Abstract Social anxiety disorder (SAD) is a highly prevalent and often disabling disorder. This paper reviews the pharmacological treatment of SAD based on published placebo-controlled studies and published meta-analyses. It addresses three specific questions: What is the first-line pharmacological treatment of SAD? How long should treatment last? What should be the management of treatment-resistant cases? Based on their efficacy for SAD and common co-morbid disorders, tolerability and safety, selective serotonin reuptake inhibitors (SSRIs) and venlafaxine should be considered the first-line treatment for most patients. Less information is available regarding the optimal length of treatment, although individuals who discontinue treatment after 12–20 wk appear more likely to relapse than those who continue on medication. Even less empirical evidence is available to support strategies for treatment-resistant cases. Clinical experience suggests that SSRI non-responders may benefit from augmentation with benzodiazepines or gabapentin or from switching to monoamine oxidase inhibitors, reversible inhibitors of monoamine oxidase A, benzodiazepines or gabapentin. Cognitive-behavioural is a well-established alternative first line therapy that may also be a helpful adjunct in non-responders to pharmacological treatment of SAD.

Pharmacological Treatment for Social Anxiety Disorder

2014 ◽  
pp. 521-546 ◽  
Author(s):  
Franklin R. Schneier ◽  
Laura B. Bragdon ◽  
Carlos Blanco ◽  
Michael R. Liebowitz
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment

Anxiety disorders in primary care

2017 ◽  
Author(s):  
Markus Dold ◽  
Siegfried Kasper
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Panic Disorder ◽  
Anxiety Disorders ◽  
Generalized Anxiety Disorder ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Treatment Options ◽  
Specific Phobia ◽  
Generalized Anxiety

Chapter 7 summarizes the epidemiology, clinical characteristics, and evidence for pharmacological treatment options of generalized anxiety disorder, panic disorder, agoraphobia, specific phobia, and social anxiety disorder. With regard to the pharmacological management, serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) represent the well-established first-line medication for generalized anxiety disorder (GAD), panic disorder, agoraphobia, and social anxiety disorder. In GAD, also the calcium channel modulator pregabalin can be regarded as evidence-based treatment option. In simple cases of specific phobia, however, the initiation of a pharmacotherapy is not recognized as standard treatment according to international treatment guidelines and psychotherapeutic interventions should be preferred. Besides illustrating the pharmacological treatment options, we described the actualized diagnostic criteria for anxiety disorders established in the newly introduced fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V).

Pharmacological treatment of social anxiety disorder: A meta-analysis

2003 ◽  
Vol 18 (1) ◽  
pp. 29-40 ◽  
Author(s):  
Carlos Blanco ◽  
Franklin R. Schneier ◽  
Andrew Schmidt ◽  
Carmen-Rosa Blanco-Jerez ◽  
Randall D. Marshall ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Pharmacological Treatment ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document